Myocardial infarction (MI) resulting from ischemic reperfusion injury (IRI) can be mitigated by pre/postconditioning. We developed bioconjugated lipid polymer hybrid nanoparticles (LPHN) to precondition the cardiac muscle cells for IRI and deliver drug to reduce the MI size. Rifampicin was encapsulated in LPHN resulting in diameter sizes ranging from 100 to 200 nm using multi-inlet vortex mixer (MIVM). Using SEM and TEM, the nanoparticles with outer lipid layer and inner polymeric core was confirmed. Using DLS and FTIR, the chemical composition and the sizes of the synthesized LPNH were confirmed. Future work of developing more efficient methods for synthesis and in vitro testing with cardiomyocytes for validation is required.
Nanoparticles Designed to Precondition the Heart for Myocardial Infarction
Advisor: Dr. Folarin Erogbogbo
Authors: Jung Han Kim